Advocacy in rare disease: Driving technology advances – 2023 Webinar
Explore how patient advocacy drives rare disease innovation, improves diagnosis, and accelerates technology-driven ad...
Volv Global personalises healthcare by providing insights on patients and diseases powered by data-driven AI and machine learning.
Our custom, proprietary, machine learning algorithms power a suite of services for pharmaceutical companies that reduces costs throughout the healthcare ecosystem and improves outcomes for those living with disease.Â
Stratify and triage patients for individualised and optimised treatment, saving time, cost and the emotional burden of incorrect diagnosis.
Characterise, segment and target patient cohorts to make clinical development and commercialisation more efficient and cost-effective.
Generate novel insights and new understanding of patient biomarkers, phenotypes, clinical features and endpoints.
Optimise resource allocation and reduce cost impact of incorrect or late diagnoses, while maximising quality of life and outcomes.
Volv Global helps you work smarter
Volv Global uses AI and population-scale data to generate knowledge and insights into difficult-to-diagnose diseases that others cannot match. Our clients can leverage these insights to enhance clinical development strategies, enrich disease understanding, and gain an edge over their rivals. Our insights help identify opportunities to rapidly develop diagnostic tools, reposition existing drugs that increase R&D viability, so our clients can target new markets, work smarter and drive profitability.
Volv Global, in numbers
Volv Global delivers high-value solutions at speed
De-risk clinical strategy & improve robustness of trial planning.
Generate meaningful and valuable real-world evidence.
Expand the boundaries of medical understanding with new RWD insights.
Launch strongly and extend the product lifecycle by finding more patients.
Driving Innovation in Rare Disease & Healthcare AI
At Volv Global, we combine advanced AI in healthcare with real-world data (RWD) to deliver transformative solutions for rare and difficult-to-diagnose disease patients. Our proprietary methodology for machine learning in healthcare technology enables:
– Detecting rare diseases faster and more accurately
– Generating real-world evidence (RWE) for clinical trials and regulatory submissions
– Optimising the patient journey with data-driven insights
– Reducing time and costs in drug development and market access
By partnering with Volv Global, pharmaceutical innovators, healthcare providers, and policymakers gain the tools to make smarter, faster, and more impactful decisions across the entire healthcare ecosystem.
Introducing inTrigue
With inTrigue, our flagship machine learning methodology, Volv Global transforms disease management and treatment at the individual patient level, along the patient journey and optimising patient outcomes.
Understanding patient phenomenology, across all diseases.
We ensure that all patients are offered the right treatment options and increase the pool of RWD on a disease.
We detect subtle patterns among biomarkers to predict disease incidence early, sometimes years ahead of time.​
We model disease progression and are able to provide prognoses, instead of diagnoses.
We detect, cluster and differentiate sub-groups within a heterogenous patient cohort, to learn more about disease pathways.
The human story
Volv Global helps transform lives by giving pharmaceutical innovators powerful insights into difficult-to-diagnose diseases so they can develop effective tools and treatments. To the patient this might look like earlier diagnosis, a lifechanging drug or the opportunity to connect with a wider community for education and support as they navigate life with a rare disease.
Stay informed
Explore how patient advocacy drives rare disease innovation, improves diagnosis, and accelerates technology-driven ad...
Reflecting on Rare Disease Day: Awareness is an Act of Love – Guest Article by Jessica Lynn of Rareatives
The diagnostic gap: stopping cancer patients from losing a winnable battle means treating earlier diagnosis as a stra...
The podcast Uncovering the uncommon: Advances in Rare Disease diagnosis explores diagnostic delays and how to shorte...
Volv Global will be exhibiting at Faces of Industrial Research (FIR) 2026 on Friday, February 20th, 2026, at the EPFL...
The podcast Uncovering the uncommon: Advances in Rare Disease diagnosis explores diagnostic delays and how to shorte...
Chronic Obstructive Pulmonary Disease remains under-recognised & under-diagnosed. How do we ensure COPD patients ...
At Rare Patient Voice, we've learned one crucial truth over the past decade:Â data can reveal patterns, but only patie...
Volv Global at Digital Lounge @Davos 2026: CEO Christopher Rudolf speaks on applied AI, cost-efficient healthcare and...
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification. Novel therapies only achieve the...
Bridging gaps across the CLL care pathway, Part 2: Knowing When To Treat – AI for Transformation, Infection Risk, and...
Bridging gaps across the CLL care pathway, Part 1: From Signal to Stratification – Reimagining Early CLL Care through...
Go​ deeper
Explore how patient advocacy drives rare disease innovation, improves diagnosis, and accelerates technology-driven ad...
The diagnostic gap: stopping cancer patients from losing a winnable battle means treating earlier diagnosis as a stra...
The podcast Uncovering the uncommon: Advances in Rare Disease diagnosis explores diagnostic delays and how to shorte...
The podcast Uncovering the uncommon: Advances in Rare Disease diagnosis explores diagnostic delays and how to shorte...
Chronic Obstructive Pulmonary Disease remains under-recognised & under-diagnosed. How do we ensure COPD patients ...
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification. Novel therapies only achieve the...
Bridging gaps across the CLL care pathway, Part 2: Knowing When To Treat – AI for Transformation, Infection Risk, and...
Bridging gaps across the CLL care pathway, Part 1: From Signal to Stratification – Reimagining Early CLL Care through...
The next multiple myeloma frontier is the creation of AI-driven diagnostic systems that recognise this cancer sooner ...
Explore how early detection, AI insights, and innovation in T1D care can align to improve outcomes. A perspective by ...
AI-driven insights & RWD in Rare Disease: Accelerate AATD Diagnosis and identify undiagnosed AATD patients earlie...
Join Volv Global CEO Christopher Rudolf at the Rare Trials Summit 2025 in Boston to explore how AI, NLP, and real-wor...